Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LLY 
Eli Lilly and Company (LLY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: LLY (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $951.98
1 Year Target Price $951.98
| 16 | Strong Buy |
| 7 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.8% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 709.79B USD | Price to earnings Ratio 64.39 | 1Y Target Price 951.98 |
Price to earnings Ratio 64.39 | 1Y Target Price 951.98 | ||
Volume (30-day avg) 29 | Beta 0.39 | 52 Weeks Range 675.71 - 967.27 | Updated Date 07/10/2025 |
52 Weeks Range 675.71 - 967.27 | Updated Date 07/10/2025 | ||
Dividends yield (FY) 0.77% | Basic EPS (TTM) 12.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 22.67% | Operating Margin (TTM) 42.49% |
Management Effectiveness
Return on Assets (TTM) 16.45% | Return on Equity (TTM) 77.28% |
Valuation
Trailing PE 64.39 | Forward PE 36.1 | Enterprise Value 741741338484 | Price to Sales(TTM) 14.48 |
Enterprise Value 741741338484 | Price to Sales(TTM) 14.48 | ||
Enterprise Value to Revenue 15.14 | Enterprise Value to EBITDA 45.58 | Shares Outstanding 897736000 | Shares Floating 895500289 |
Shares Outstanding 897736000 | Shares Floating 895500289 | ||
Percent Insiders 0.16 | Percent Institutions 83.96 |
Upturn AI SWOT
Eli Lilly and Company
Company Overview
History and Background
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. It has grown from a small laboratory into a global pharmaceutical leader, pioneering the mass production of penicillin during World War II and developing innovative medicines for diabetes, cancer, and other diseases.
Core Business Areas
- Human Pharmaceutical Products: Focuses on the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products. Includes treatments for diabetes, oncology, immunology, neuroscience, and other therapeutic areas.
- Animal Health: Develops and markets products for companion animals and livestock. This segment focuses on preventing and treating diseases in animals, improving animal health and productivity.
Leadership and Structure
David A. Ricks is the Chairman and CEO. The company is structured into global business units focusing on specific therapeutic areas, supported by centralized research and development, manufacturing, and commercial functions.
Top Products and Market Share
Key Offerings
- Mounjaro (Tirzepatide): A dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes. In Q4 2023, Mounjaro generated $2.2 billion in revenue. Competitors include Ozempic (Novo Nordisk) and other GLP-1 receptor agonists.
- Trulicity (Dulaglutide): A GLP-1 receptor agonist for the treatment of type 2 diabetes. While facing increasing competition, Trulicity remains a significant revenue generator. Competitors include Ozempic (Novo Nordisk) and Rybelsus (Novo Nordisk).
- Verzenio (Abemaciclib): A CDK4/6 inhibitor for the treatment of certain types of breast cancer. Growing use of Verzenio and its market share is increasing, although competitors are Pfizer and Novartis.
- Emgality (Gepants): A CGRP inhibitor for the prevention of migraines. Emgality continues to establish itself in the competitive migraine treatment market, with competition coming from other CGRP inhibitors like Aimovig and Ajovy.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and patent protection. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology.
Positioning
Eli Lilly and Company is a leading pharmaceutical company with a strong pipeline of innovative medicines. Its competitive advantage lies in its research and development capabilities, strong brands, and global presence.
Total Addressable Market (TAM)
The global pharmaceuticals market is expected to reach over $1.7 trillion by 2027. Eli Lilly and Company is positioned to capture a significant portion of this market through its diverse portfolio and innovative pipeline.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Diverse product portfolio
- Global presence
- Established brand reputation
- Experienced management team
Weaknesses
- Patent expirations
- High R&D costs
- Dependence on key products
- Exposure to litigation
- Pricing pressures
Opportunities
- Expansion into emerging markets
- Development of new therapies for unmet medical needs
- Strategic acquisitions and partnerships
- Leveraging digital health technologies
- Growth in personalized medicine
Threats
- Generic competition
- Regulatory changes
- Economic downturns
- Increased competition
- Drug pricing regulations
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- NVS
- ABBV
Competitive Landscape
Eli Lilly and Company faces competition from other large pharmaceutical companies and generic drug manufacturers. It differentiates itself through its innovative pipeline and focus on specific therapeutic areas.
Major Acquisitions
Sigilon Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 346
- Strategic Rationale: Sigilon's Shielded Living Therapeuticsu2122 platform technology to create cell-based therapies focused on type 1 diabetes.
Growth Trajectory and Initiatives
Historical Growth: Eli Lilly and Company has experienced solid growth in recent years, driven by new product launches and strategic acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for Eli Lilly and Company, driven by its strong pipeline and increasing demand for its products.
Recent Initiatives: Recent initiatives include the launch of Mounjaro, acquisitions of smaller biotech firms, and investments in digital health technologies.
Summary
Eli Lilly is a strong pharmaceutical company with a robust pipeline and diverse product portfolio. Its financial performance is solid, and it is well-positioned for future growth. However, patent expirations and increasing competition pose potential challenges that the company needs to manage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Eli Lilly and Company Investor Relations
- SEC Filings
- Analyst Reports
- Market Research Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eli Lilly and Company
Exchange NYSE | Headquaters Indianapolis, IN, United States | ||
IPO Launch date 1978-01-13 | Chairman, CEO & President Mr. David A. Ricks | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 47000 | Website https://www.lilly.com |
Full time employees 47000 | Website https://www.lilly.com | ||
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.